Ming  Hsieh net worth and biography

Ming Hsieh Biography and Net Worth

Ming Hsieh, our founder, served as the manager of our predecessor, Fulgent Therapeutics LLC (“Fulgent LLC”), from its inception in June 2011 until September 2016, was appointed as our director and Chief Executive Officer upon our incorporation in May 2016 and was appointed as Chair of our Board in September 2016 in connection with our initial public offering. Mr. Hsieh also served as the President of the Company from its inception to May 2022. Prior to founding our Company, Mr. Hsieh served as Chief Executive Officer, President and Chairperson of the board of directors of Cogent, Inc., a biometric identification services and products company he co-founded in 1990, which was acquired by 3M in 2010. Prior to his tenure at Cogent, Mr. Hsieh founded and served as Vice President of AMAX Technology from 1987 to 1990. Mr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the Nasdaq Global Select Market. Mr. Hsieh received a B.S.E.E. from the University of Southern California in 1983 and an M.S.E.E. from the University of Southern California in 1984, as well as honorary doctoral degrees from the University of Southern California in 2010 and the University of West Virginia in 2011. Mr. Hsieh has served as a trustee at the University of Southern California since 2007 and at Fudan University in China since 2011. In 2015, Mr. Hsieh was elected to the National Academy of Engineering. In 2017, Mr. Hsieh was elected to the National Academy of Inventors. Mr. Hsieh was selected to serve on our Board based on his extensive management experience, his knowledge of our business, culture and operations as our founder, his engineering expertise and his service for and leadership of our Company since inception.

What is Ming Hsieh's net worth?

The estimated net worth of Ming Hsieh is at least $19.92 million as of November 25th, 2024. Hsieh owns 703,711 shares of Fulgent Genetics stock worth more than $19,915,021 as of December 5th. This net worth evaluation does not reflect any other investments that Hsieh may own. Additionally, Hsieh receives a salary of $2,310,000.00 as CEO at Fulgent Genetics. Learn More about Ming Hsieh's net worth.

How old is Ming Hsieh?

Hsieh is currently 68 years old. There are 4 older executives and no younger executives at Fulgent Genetics. Learn More on Ming Hsieh's age.

What is Ming Hsieh's salary?

As the CEO of Fulgent Genetics, Inc., Hsieh earns $2,310,000.00 per year. Learn More on Ming Hsieh's salary.

How do I contact Ming Hsieh?

The corporate mailing address for Hsieh and other Fulgent Genetics executives is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. Fulgent Genetics can also be reached via phone at (626) 350-0537 and via email at [email protected]. Learn More on Ming Hsieh's contact information.

Has Ming Hsieh been buying or selling shares of Fulgent Genetics?

Ming Hsieh has not been actively trading shares of Fulgent Genetics during the past quarter. Most recently, Ming Hsieh sold 2,227 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.26, for a transaction totalling $40,665.02. Following the completion of the sale, the chief executive officer now directly owns 703,711 shares of the company's stock, valued at $12,849,762.86. Learn More on Ming Hsieh's trading history.

Who are Fulgent Genetics' active insiders?

Fulgent Genetics' insider roster includes John Bolger (Director), Hanlin Gao (Insider), Ming Hsieh (Chairman & CEO ), Ming Hsieh (CEO), Paul Kim (CFO), and Jian Xie (COO). Learn More on Fulgent Genetics' active insiders.

Are insiders buying or selling shares of Fulgent Genetics?

During the last twelve months, Fulgent Genetics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,596,000.00. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 24,061 shares worth more than $634,948.21. The most recent insider tranaction occured on December, 2nd when COO Jian Xie sold 1,140 shares worth more than $32,296.20. Insiders at Fulgent Genetics own 31.8% of the company. Learn More about insider trades at Fulgent Genetics.

Information on this page was last updated on 12/2/2025.

Ming Hsieh Insider Trading History at Fulgent Genetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2024Sell2,227$18.26$40,665.02703,711View SEC Filing Icon  
8/27/2024Sell2,313$22.83$52,805.79707,275View SEC Filing Icon  
3/5/2019Buy8,739$4.95$43,258.056,579,326View SEC Filing Icon  
11/13/2018Buy10,880$3.59$39,059.206,570,587View SEC Filing Icon  
11/9/2018Buy10,000$3.36$33,600.00View SEC Filing Icon  
11/30/2017Buy2,000$3.60$7,200.006,549,707View SEC Filing Icon  
11/20/2017Buy7,259$3.28$23,809.526,540,849View SEC Filing Icon  
11/16/2017Buy2,205$3.23$7,122.156,540,849View SEC Filing Icon  
11/14/2017Buy10,504$3.30$34,663.20View SEC Filing Icon  
11/9/2017Buy11,520$3.47$39,974.406,506,464View SEC Filing Icon  
6/15/2017Buy20,000$5.26$105,200.006,482,244View SEC Filing Icon  
6/13/2017Buy30,000$4.98$149,400.006,459,944View SEC Filing Icon  
9/30/2016Buy1,000,000$9.00$9,000,000.00View SEC Filing Icon  
See Full Table

Ming Hsieh Buying and Selling Activity at Fulgent Genetics

This chart shows Ming Hsieh's buying and selling at Fulgent Genetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fulgent Genetics Company Overview

Fulgent Genetics logo
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Read More

Today's Range

Now: $28.30
Low: $27.52
High: $28.60

50 Day Range

MA: $25.36
Low: $22.30
High: $30.85

2 Week Range

Now: $28.30
Low: $14.57
High: $31.04

Volume

160,380 shs

Average Volume

390,334 shs

Market Capitalization

$874.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65